arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Dianthus Therapeutics, Inc. /DE/

DNTH

$83.16 ▼ -2.64 (-3.08%) at close

11 Visible periods

24 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Dianthus Therapeutics, Inc. /DE/ faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $3.2B

Dividend Yield —

Revenue Growth -67.3% ↘

Op. Margin —

ROIC -28.5% ↘

FCF / Share $-3.34 ↘

Trailing P/E —

Price / Book 7.3x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Nov 5, 2026.

11-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$2.04M

↓ -67.3% —

Net Income Profit after all expenses

$-162.34M

↓ -91.1% —

FCF / Share Free cash flow per share

$-3.34

↓ -42.4% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↑

Cash Quality ↓

Dividend History

Dividend / share · sourced from SEC filings

$0.00 Latest / share

FY 2015

FY 2016

FY 2017

FY 2018

FY 2019

FY 2020

FY 2021

FY 2022

FY 2023

$0.00

FY 2024

$0.00

FY 2025

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗
Revenue Growth YoY (%)	-67.3% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-942%)	120.6% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1408%)	—	—	—	—	—	—	—	—	—
EPS Growth YoY (%)	-64.7% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	69.8% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	74.1% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-2424.8% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	24.6% Good Good Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—
Net Income Growth YoY (%)	-91.1% Weak ↓ Weak Declining Year-over-year change in net income	-95.1% Weak ↓ Weak Declining Year-over-year change in net income	-53.0% Weak ↓ Weak Declining Year-over-year change in net income	60.0% Excellent ↑ Excellent Improving Year-over-year change in net income	5.1% Fair ↑ Fair Improving Year-over-year change in net income	2.4% Caution ↑ Caution Improving Year-over-year change in net income	-33.5% Weak ↑ Weak Improving Year-over-year change in net income	-62.1% Weak Weak Year-over-year change in net income	-276.3% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-42.4% Weak ↑ Weak Improving Year-over-year change in free cash flow	67.2% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	78.5% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-2905.4% Weak Weak Year-over-year change in free cash flow	24.6% Good Good Year-over-year change in free cash flow	—	—	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗
FCF / Net Income (x)	0.80x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.92x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.85x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.02x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.85x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.86x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.78x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.86x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.69x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.71x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗
Return on Invested Capital (%)	-28.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-22.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-22.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	52.9% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-34.2% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-43.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-46.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-32.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	67.0% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	82.5% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-33.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-27.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-26.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-35.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-39.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-48.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-51.4% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-38.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	-65.6% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-32.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-319%)	-24.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-261%)	-25.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-272%)	64.2% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+328%)	-41.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-375%)	-52.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-447%)	-54.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-462%)	-39.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-363%)	84.3% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+462%)	106.3% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+609%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗
Interest Coverage (x)	—	—	—	—	—	—	—	—	—	-56.86x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-51.09M	$-22.79M	$-132.32M	$-15.37M	$-131.65M	$-58.15M	$-65.07M	$-58.34M	$-51.40M	—	—

📊 What does each share earn? 8 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗
Revenue per Share (USD)	$0.05	$0.19	$0.55	—	—	—	—	—	—	—	—
Basic EPS, GAAP (USD)	$-4.20	$-2.55	$-8.45	$-32.57	$-1.29	$-1.71	—	—	—	—	—
Free Cash Flow per Share (USD)	$-3.34	$-2.35	$-7.15	$-33.25	$-1.11	$-1.47	—	—	—	—	—
Dividend per Share (USD)	$0.00	$0.00	—	—	—	—	—	—	—	—	—
Book Value per Share (USD)	$11.42	$11.33	$11.40	$-50.69	$2.94	$2.97	$3.60	$4.37	$-17.91	—	—
Tangible Book Value per Share (USD)	$11.42	$11.33	$11.40	$-50.69	$2.94	$2.97	$3.60	$4.37	$-17.91	—	—
Basic Weighted Avg Shares (shares)	38.62M	33.31M	5.15M	874,234	54.95M	43.92M	—	—	—	—	—
Dividend Payout Ratio (%)	0.0% Excellent Excellent Dividends paid as a percentage of earnings Optimal: 30-60%	0.0% Excellent Excellent Dividends paid as a percentage of earnings Optimal: 30-60%	—	—	—	—	—	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗
Working Capital (USD)	$378.71M	$262.45M	$167.82M	$73.81M	$169.83M	$140.10M	$135.73M	$134.90M	$48.36M	—	—
Total Equity (USD)	$493.40M	$352.48M	$168.87M	$-44.37M	$172.67M	$143.91M	$141.19M	$145.65M	$-42.12M	$-8.87M	$-289.00K

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗
Sales/Revenue/Turnover (USD)	$2.04M	$6.24M	$2.83M	—	—	—	$0.00	$0.00	$0.00	$0.00	—
Depreciation Expense (USD)	$111.00K	$96.00K	$67.00K	$30.00K	$2.02M	$1.98M	$1.84M	$875.00K	$376.00K	$6.00K	—
Net Income, GAAP (USD)	$-162.34M	$-84.97M	$-43.55M	$-28.48M	$-71.14M	$-74.94M	$-76.77M	$-57.52M	$-35.49M	$-9.43M	—
Operating Cash Flow (USD)	$-129.06M	$-78.18M	$-36.86M	$-29.07M	$-59.53M	$-64.02M	$-57.10M	$-41.89M	$-22.26M	$-6.53M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 11 years · 40 quarters

Dianthus Therapeutics, Inc. /DE/

Analytical Summary

11-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Dividend History

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare DNTH with peers